In short
AKG is a citric acid cycle intermediate and a required cofactor for enzymes that regulate DNA methylation and collagen synthesis. Circulating levels decline with age. Animal lifespan data is good, human data is one small uncontrolled study, and no randomised controlled trial has reported biological age outcomes.
Alpha-ketoglutarate, also written as 2-oxoglutarate, is one of the more interesting molecules in the longevity conversation, partly because it is not exotic. Your cells make it continuously. The question is what happens when there is less of it.
Two jobs, both relevant to ageing
Energy metabolism
AKG is an intermediate in the citric acid cycle, the pathway that turns fuel into usable cellular energy. It sits at a control point: the conversion of isocitrate to alpha-ketoglutarate is one of the cycle's rate-limiting steps. It is also a node where carbon and nitrogen metabolism connect, linking energy production with amino acid handling.
Enzyme cofactor
This is the part that makes AKG interesting beyond basic metabolism. It is a required cofactor for a family of more than sixty alpha-ketoglutarate-dependent dioxygenases, including:
- TET enzymes, which drive DNA demethylation. These are directly relevant to epigenetic age, because epigenetic clocks read methylation patterns.
- JmjC histone demethylases, which regulate chromatin state and gene accessibility.
- Prolyl hydroxylases, required for collagen cross-linking and stability, and involved in oxygen sensing through the HIF pathway.
If AKG availability constrains these enzymes, the downstream effects touch epigenetic regulation, gene expression and structural protein quality at once. That is why the molecule attracted attention.
The age-related decline
Circulating AKG falls substantially with age, and the commonly quoted figure is a large fold-decrease between middle age and later life. Treat the precise multiple with some caution, because the underlying human measurement data is more limited than the frequency of the citation suggests. The direction of the finding is better supported than the exact number.
Dietary intake does not meaningfully offset this. AKG occurs in food only in small amounts, and it is not a nutrient with an established intake requirement.
What has been shown, and at what strength
| Evidence | Design | Strength |
|---|---|---|
| Mouse lifespan and healthspan extension | Controlled animal study, Ca-AKG from middle age | Good design. Median lifespan extension around 12%, with notable compression of frailty. Species relevance is the limit. |
| Human DNA methylation age reduction | Retrospective, uncontrolled, n=42, self-selected | Hypothesis-generating only. No control group, commercial connection to the product. |
| Observational cohort associations | Cross-sectional, healthy population | Cannot separate the compound from the person taking it. |
| Mechanistic and cell work | In vitro and biochemical | Well established as a cofactor. Does not establish a clinical effect. |
| Randomised controlled trial on biological age | — | None published. |
Bioavailability, the real formulation problem
AKG has a short plasma half-life. Taken as a conventional immediate-release form, a dose is absorbed and cleared quickly, which produces a sharp peak and a rapid fall rather than the sustained availability that a cofactor role would theoretically favour.
This is the argument behind sustained-release formulation, and it is a reasonable engineering response to a real pharmacokinetic problem. It is also worth being precise about what it does and does not establish: improving a delivery profile is a formulation achievement, not evidence of a clinical outcome. We cover the distinction in the sustained-release explainer.
Calcium AKG specifically
Most commercial products use calcium alpha-ketoglutarate rather than the free acid, because the calcium salt is more stable to manufacture, store and formulate. The mouse lifespan study and the small human analysis both used the calcium salt form, which is why it has become the category default.
The honest summary
AKG has a coherent mechanism, strong animal data, thin human data, and a plausible formulation story. It is one of the more scientifically interesting compounds in the longevity supplement category and it is still an early-stage candidate. Both of those are true at once.
If you want the human evidence taken apart study by study, that is on the AKG evidence page. If you want to understand what biological age measurement can and cannot tell you first, start with what biological age is.
Common questions
What does alpha-ketoglutarate do in the body?
Two main things. It is an intermediate in the citric acid cycle, so it participates directly in cellular energy production. It is also a required cofactor for over sixty dioxygenase enzymes, including the TET enzymes involved in DNA demethylation and the prolyl hydroxylases required for collagen stability.
Does AKG really decline with age?
The direction of the finding is supported: circulating AKG is lower in older people. The very large fold-decrease figures often quoted in marketing rest on more limited human measurement data than the frequency of the claim suggests.
How much AKG is in food?
Very little. It is present in small quantities in some foods but there is no established dietary requirement and diet is not a practical route to supplemental-level intake.
Is there a randomised controlled trial on AKG and biological age?
Not one that has published biological age outcomes. The human evidence is currently a small retrospective uncontrolled analysis plus observational associations.